Hexarelin vs Ipamorelin
A side-by-side research comparison of Hexarelin and Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Hexarelin | Ipamorelin |
|---|---|---|
| Full name | Hexarelin (Examorelin) | Ipamorelin (Selective GH Secretagogue) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Research compound |
| Mechanism | Potent GHSR-1a agonist producing maximal pituitary GH output. Additionally binds cardiac CD36, providing cardioprotection through anti-apoptotic mechanisms independent of GH. | Selectively activates GHSR on pituitary somatotrophs. Unlike GHRP-6 and hexarelin, does not significantly activate ACTH or prolactin-releasing pathways. |
| Molecular weight | 887 Da | 711.9 Da |
| Half-life | 1-2 hours | 2 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 100-200 mcg | 100-300 mcg |
| Frequency | 2-3x daily | 1-3x daily |
| Route | Subcutaneous | Subcutaneous injection |
Hexarelin reported benefits
- Strongest GH release
- Cardioprotective effects
- Recovery acceleration
- Anti-fibrotic (cardiac)
- Neuroprotective potential
Ipamorelin reported benefits
- Clean GH release
- No cortisol or prolactin increase
- Improved sleep
- Fat loss
- Joint support
- Anti-aging benefits
Related comparisons
Research and educational reference only. Not medical advice.